Non-Viral Drug Delivery Systems Market is driven by Rising Biologic Therapeutics
Non-viral drug delivery systems encompass a diverse array of formulations and devices designed to transport therapeutic agents—such as peptides, proteins, nucleic acids, and small molecule drugs—across biological barriers without using viral vectors. These platforms include lipid nanoparticles, polymeric nanoparticles, liposomes, dendrimers, and micelles, offering advantages like reduced immunogenicity, enhanced stability, and controlled release profiles. The ability to fine-tune carrier size, surface charge, and targeting ligands enables improved bioavailability and targeted delivery to specific tissues or cells, mitigating off-target effects and enhancing treatment efficacy.
Growing concerns over safety risks associated with viral vectors, such as insertional mutagenesis and host immune responses, have spurred interest in non-viral alternatives. Moreover, the surge in biologic therapeutics, including mRNA and siRNA-based treatments, has amplified the need for robust delivery platforms that can protect fragile molecules and ensure efficient cellular uptake. Continuous innovation in material science and nanotechnology has facilitated the design of biocompatible carriers capable of overcoming physiological barriers, boosting market opportunities for pharmaceutical and biotech companies. As personalized medicine gains tractionNon-Viral Drug Delivery Systems Market solutions are poised to play a pivotal role in next-generation therapies.
The non-viral drug delivery systems market is estimated to be valued at USD 9.23 Bn in 2025 and is expected to reach USD 23.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.00% from 2025 to 2032.
Key Takeaways
Key players operating in the Non-Viral Drug Delivery Systems Market are:
-Arcturus Therapeutics
-Bio-Path Holdings
-CureVac
-Entos Pharmaceuticals
-The RNA Immunotherapies
These market players leverage their expertise in nanoparticle formulation, polymer chemistry, and nucleic acid therapeutics to expand their product portfolios. For instance, Arcturus Therapeutics’ lipid nanoparticle-based mRNA delivery platforms and CureVac’s proprietary mRNA technology highlight the convergence of drug delivery innovation with cutting-edge biologic pipelines. Bio-Path Holdings focuses on synthetic packaging vehicles for oligonucleotide therapies, while Entos Pharmaceuticals advances Fusogenix®, a liposomal system for gene editing. eTheRNA Immunotherapies specializes in RNA-based cancer vaccines, underscoring the critical role of non-viral carriers in oncology. The competitive landscape is shaped by ongoing collaborations, licensing agreements, and strategic acquisitions aimed at enhancing market share and streamlining market entry.
Growing demand in the non-viral drug delivery systems market is driven by escalating research investments and robust market growth strategies adopted by pharmaceutical companies. A surge in chronic disease prevalence—ranging from cancer and genetic disorders to cardiovascular and metabolic conditions—has elevated the urgency for targeted, long-acting therapeutics. Market research underscores the importance of overcoming physiological barriers such as the blood-brain barrier and mucosal membranes, spurring development of innovative carriers that can navigate these challenges. Additionally, the advent of RNA-based vaccines during the COVID-19 pandemic validated lipid nanoparticle platforms, accelerating interest in non-viral vectors across multiple therapeutic segments. As healthcare stakeholders prioritize patient safety and cost-effective manufacturing, non-viral technologies offer scalable solutions with lower biosafety requirements than their viral counterparts. Market insights indicate that increased regulatory clarity and supportive policies on advanced therapy medicinal products (ATMPs) will further drive adoption and unlock new market opportunities.
‣ Non-Viral Drug Delivery Systems Market: https://www.coherentmi.com/industry-reports/non-viral-drug-delivery-systems-market
Non-viral drug delivery systems encompass a diverse array of formulations and devices designed to transport therapeutic agents—such as peptides, proteins, nucleic acids, and small molecule drugs—across biological barriers without using viral vectors. These platforms include lipid nanoparticles, polymeric nanoparticles, liposomes, dendrimers, and micelles, offering advantages like reduced immunogenicity, enhanced stability, and controlled release profiles. The ability to fine-tune carrier size, surface charge, and targeting ligands enables improved bioavailability and targeted delivery to specific tissues or cells, mitigating off-target effects and enhancing treatment efficacy.
Growing concerns over safety risks associated with viral vectors, such as insertional mutagenesis and host immune responses, have spurred interest in non-viral alternatives. Moreover, the surge in biologic therapeutics, including mRNA and siRNA-based treatments, has amplified the need for robust delivery platforms that can protect fragile molecules and ensure efficient cellular uptake. Continuous innovation in material science and nanotechnology has facilitated the design of biocompatible carriers capable of overcoming physiological barriers, boosting market opportunities for pharmaceutical and biotech companies. As personalized medicine gains tractionNon-Viral Drug Delivery Systems Market solutions are poised to play a pivotal role in next-generation therapies.
The non-viral drug delivery systems market is estimated to be valued at USD 9.23 Bn in 2025 and is expected to reach USD 23.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.00% from 2025 to 2032.
Key Takeaways
Key players operating in the Non-Viral Drug Delivery Systems Market are:
-Arcturus Therapeutics
-Bio-Path Holdings
-CureVac
-Entos Pharmaceuticals
-The RNA Immunotherapies
These market players leverage their expertise in nanoparticle formulation, polymer chemistry, and nucleic acid therapeutics to expand their product portfolios. For instance, Arcturus Therapeutics’ lipid nanoparticle-based mRNA delivery platforms and CureVac’s proprietary mRNA technology highlight the convergence of drug delivery innovation with cutting-edge biologic pipelines. Bio-Path Holdings focuses on synthetic packaging vehicles for oligonucleotide therapies, while Entos Pharmaceuticals advances Fusogenix®, a liposomal system for gene editing. eTheRNA Immunotherapies specializes in RNA-based cancer vaccines, underscoring the critical role of non-viral carriers in oncology. The competitive landscape is shaped by ongoing collaborations, licensing agreements, and strategic acquisitions aimed at enhancing market share and streamlining market entry.
Growing demand in the non-viral drug delivery systems market is driven by escalating research investments and robust market growth strategies adopted by pharmaceutical companies. A surge in chronic disease prevalence—ranging from cancer and genetic disorders to cardiovascular and metabolic conditions—has elevated the urgency for targeted, long-acting therapeutics. Market research underscores the importance of overcoming physiological barriers such as the blood-brain barrier and mucosal membranes, spurring development of innovative carriers that can navigate these challenges. Additionally, the advent of RNA-based vaccines during the COVID-19 pandemic validated lipid nanoparticle platforms, accelerating interest in non-viral vectors across multiple therapeutic segments. As healthcare stakeholders prioritize patient safety and cost-effective manufacturing, non-viral technologies offer scalable solutions with lower biosafety requirements than their viral counterparts. Market insights indicate that increased regulatory clarity and supportive policies on advanced therapy medicinal products (ATMPs) will further drive adoption and unlock new market opportunities.
‣ Non-Viral Drug Delivery Systems Market: https://www.coherentmi.com/industry-reports/non-viral-drug-delivery-systems-market
Non-Viral Drug Delivery Systems Market is driven by Rising Biologic Therapeutics
Non-viral drug delivery systems encompass a diverse array of formulations and devices designed to transport therapeutic agents—such as peptides, proteins, nucleic acids, and small molecule drugs—across biological barriers without using viral vectors. These platforms include lipid nanoparticles, polymeric nanoparticles, liposomes, dendrimers, and micelles, offering advantages like reduced immunogenicity, enhanced stability, and controlled release profiles. The ability to fine-tune carrier size, surface charge, and targeting ligands enables improved bioavailability and targeted delivery to specific tissues or cells, mitigating off-target effects and enhancing treatment efficacy.
Growing concerns over safety risks associated with viral vectors, such as insertional mutagenesis and host immune responses, have spurred interest in non-viral alternatives. Moreover, the surge in biologic therapeutics, including mRNA and siRNA-based treatments, has amplified the need for robust delivery platforms that can protect fragile molecules and ensure efficient cellular uptake. Continuous innovation in material science and nanotechnology has facilitated the design of biocompatible carriers capable of overcoming physiological barriers, boosting market opportunities for pharmaceutical and biotech companies. As personalized medicine gains tractionNon-Viral Drug Delivery Systems Market solutions are poised to play a pivotal role in next-generation therapies.
The non-viral drug delivery systems market is estimated to be valued at USD 9.23 Bn in 2025 and is expected to reach USD 23.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 14.00% from 2025 to 2032.
Key Takeaways
Key players operating in the Non-Viral Drug Delivery Systems Market are:
-Arcturus Therapeutics
-Bio-Path Holdings
-CureVac
-Entos Pharmaceuticals
-The RNA Immunotherapies
These market players leverage their expertise in nanoparticle formulation, polymer chemistry, and nucleic acid therapeutics to expand their product portfolios. For instance, Arcturus Therapeutics’ lipid nanoparticle-based mRNA delivery platforms and CureVac’s proprietary mRNA technology highlight the convergence of drug delivery innovation with cutting-edge biologic pipelines. Bio-Path Holdings focuses on synthetic packaging vehicles for oligonucleotide therapies, while Entos Pharmaceuticals advances Fusogenix®, a liposomal system for gene editing. eTheRNA Immunotherapies specializes in RNA-based cancer vaccines, underscoring the critical role of non-viral carriers in oncology. The competitive landscape is shaped by ongoing collaborations, licensing agreements, and strategic acquisitions aimed at enhancing market share and streamlining market entry.
Growing demand in the non-viral drug delivery systems market is driven by escalating research investments and robust market growth strategies adopted by pharmaceutical companies. A surge in chronic disease prevalence—ranging from cancer and genetic disorders to cardiovascular and metabolic conditions—has elevated the urgency for targeted, long-acting therapeutics. Market research underscores the importance of overcoming physiological barriers such as the blood-brain barrier and mucosal membranes, spurring development of innovative carriers that can navigate these challenges. Additionally, the advent of RNA-based vaccines during the COVID-19 pandemic validated lipid nanoparticle platforms, accelerating interest in non-viral vectors across multiple therapeutic segments. As healthcare stakeholders prioritize patient safety and cost-effective manufacturing, non-viral technologies offer scalable solutions with lower biosafety requirements than their viral counterparts. Market insights indicate that increased regulatory clarity and supportive policies on advanced therapy medicinal products (ATMPs) will further drive adoption and unlock new market opportunities.
‣ Non-Viral Drug Delivery Systems Market: https://www.coherentmi.com/industry-reports/non-viral-drug-delivery-systems-market
0 Comments
0 Shares